Currently, glypican-3 (GPC-3) has been tested to modify CAR-T-cells to treat HCC (NCT02715362, NCT03198546, and NCT02905188), as described [87], as well as for colorectal cancers (NCT02416466, NCT02850536, and NCT00004178). This evidence concerns the gene GPC3 and hepatocellular carcinoma.